An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Trial Profile

An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 27 Sep 2017 Planned End Date changed from 31 Mar 2019 to 1 Oct 2018.
    • 27 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2018.
    • 28 Oct 2016 Status changed from not yet recruiting to recruiting, as per Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top